- Following the positive P-I results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant
- The study will evaluate the immunogenicity and safety profile of the chosen formulation and dosing regimen of CoVLP (two doses of 3.75µg combined with GSK’s adjuvant given 21 days apart) in healthy adults 18-64yrs. of age and in elderly subjects aged ≥65yrs.
- P-II trials will be conducted in multiple locations across Canada and, upon FDA’s approval, in the US. The P-III studies will start before the end of 2020 and will evaluate CoVLP in ~30,000 volunteers globally
Click here to read full press release/ article | Ref: GSK | Image: BioPharma Reporter